CR Double-Crane subsidiary gains drug approval, sets investor briefing

China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane) announced that its wholly-owned subsidiary, Beijing WanHui Double-Crane Pharmaceutical Co., Ltd., has obtained a drug registration certificate for alfacalcidol soft capsules from the National Medical Products Administration. This Type 4 chemical drug, with a 0.25 µg specification, is indicated for treating calcium metabolism disorders caused by insufficient 1,25-dihydroxyvitamin D3 production, including renal osteodystrophy and osteoporosis. The approval, received on October 14, 2025, follows an application submitted on June 18, 2024, and is considered equivalent to passing a consistency evaluation. CR Double-Crane has invested CNY 493.02 million in the drug's research and development.

Globally, alfacalcidol soft capsules generated $182 million in sales in 2024. In China, nine enterprises, including WanHui Double-Crane, are approved to produce the drug. The domestic market saw total sales (terminal price) of CNY 659 million in 2024, with Qingdao Guoxin Pharmaceutical leading with a 36.53% market share. The new registration certificate will enrich CR Double-Crane's product line and enhance its market competitiveness.

In a related development, CR Double-Crane will host an investor briefing on October 28, 2025, from 10:00 to 11:30 AM (Beijing time) to discuss its Q3 2025 operating results and financial condition. The briefing will be held in person, online, and via teleconference, with key executives, including chairman Lu Wenchao, in attendance.